1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Endo's New Chief Has Challenges Ahead

As Firm's US Generics Sales Continue To Suffer

 
• By Dean Rudge

Set to take charge of the company on 6 March, Endo's incoming chief Blaise Coleman must tackle Endo's multi-billion-dollar debt and steer the firm back to profitability after several years of significant losses.

Hurdles
Replacing Paul Campanelli, Blaise Coleman has challenges ahead • Source: Shutterstock

Endo’s president and chief executive officer designate Blaise Coleman told investors he was “honored and excited to lead Endo in its next phase,” as the US firm reported another full year of struggling sales for its US non-injectable Generics unit and another overall sizable financial loss.

Stepping up from the role of chief financial officer on 6 March to take over from Paul Campanelli, who will...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business